SCHEMBL3015847

SCHEMBL3015847

COc1ccc(Br)cc1S(=O)(=O)N1CCN(c2nc(-c3cc(OC)c(OC)c(OC)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 3/20 0.56
MAPT P10636 4/20 0.48
RECQL P46063 2/20 0.48
USP2 O75604 2/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45
ALOX15 P16050 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NTSR1 P30989 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013965 0.91 SMN1; SMN2 (0.59) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3022136 0.91 MAPK1 (0.54) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3020067 0.91 MAPT (0.54) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3011599 0.91 GAA (0.54) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3013585 0.90 GAA (0.53) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3003833 0.90 MAPT (0.54) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3009767 0.90 ALDH1A1 (0.57) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3020045 0.90 LMNA (0.59) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3011654 0.89 POLB (0.56) GAAALDH1A1MAPK1MAPTRECQL
SCHEMBL3011013 0.89 GAA (0.54) GAAALDH1A1MAPK1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885ALDH1A1 3510/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.